Patent ID: 8834869
Filing Date: 2014-09-16
Classification: A61K,A61P,C12Y

Abstract:
1. A method of treating a vitreoretinal disease or disorder, or of treating a complication of a vitreoretinal disease or disorder, of an eye of a subject, comprising contacting the vitreous in the eye of the subject with an effective amount of a microplasmin and with an effective amount of a second agent, wherein said second agent is selected from the group consisting of hyaluronidase, chondroitinase ABC, chondroitinase AC, chondroitinase B, chondroitin 4-sulfatase, chondroitin 6-sulfatase, β-glucuronidase, collagenase, dispase, RGD containing peptides, echistatin, falvoridin, anti-integrin antibody, P2Y receptor antagonists, urea, hydroxyurea, thiourea, anti-angiogenic agents, vascular endothelial growth factor (VEGF) inhibitors, placental growth factor (P1GF) inhibitors, and any combinations thereof, thereby treating the vitreoretinal disease or disorder, or the complication of the vitreoretinal disease or disorder, of the eye of the subject.